Biotin immunoassay interference: A UK-based prevalence study.

A Sanders, R Gama, H Ashby, P Mohammed

Annals of clinical biochemistry 2021 Jan

filter terms:

Biotin interference in biotin-streptavidin-based immunoassays is increasingly reported due to individuals taking biotin-containing supplements and patients prescribed biotin. The reported prevalence of serum biotin above the lowest threshold (≥10 µg/L) for interference in Roche Diagnostics immunoassay tests is 0.8% in Australia and 7.4% in the USA. There are, however, no such data in UK populations. In a service evaluation, we therefore studied the prevalence of biotin interference in routine serum samples received in our laboratory. Biotin was measured in 524 anonymized surplus serum samples in which at least one immunoassay test had been requested. The median (95% confidence intervals) for serum biotin was 0.27 µg/L (0.07-0.93 µg/L). Serum biotin was <10 µg/L in all samples, <5 µg/L in 522 (99.6%) and <1 µg/L in 513 (98.1%) samples. In four samples, serum biotin was ≥2.5 µg/L (0.8%). These data indicate that the probability of biotin immunoassay interference in our patient population is extremely low, with the exception of assays reporting the lowest interference thresholds (e.g. Ortho Troponin I assay [threshold ≥2.5 µg/L]).

Citation

A Sanders, R Gama, H Ashby, P Mohammed. Biotin immunoassay interference: A UK-based prevalence study. Annals of clinical biochemistry. 2021 Jan;58(1):66-69